UNBELIEVABLE: 4 | History Defined

Nearly 600 FDA Postmarket Drug Studies Are Behind Schedule While Many of the Medicines Stay on the Market

Nearly 600 postmarket studies of FDA-approved drugs and biologics are behind schedule. What the delays mean for patients and how to check a study's status.

Medical Daily · Sep 22

Recalled Saline Flush Ampules Used on IV Lines and Ports Receive FDA's Most Serious Rating Over Sterility Concerns

FDA rated the Spectra saline flush ampule recall as its most serious type due to sterility risks. What patients with IV lines and ports should know now.

Medical Daily · Sep 22

Nitazenes Implicated in 76 Scottish Deaths in 2024 Are Turning Up in Counterfeit Pills from Europe to Louisiana

Nitazenes, implicated in 76 Scottish drug deaths, now appear in fake pills across Europe and the U.S. What families should know about the risk.

Medical Daily · Sep 22

Amneal Launches Its Generic Lanreotide Immediately While the Brand Still Posts Nearly a Billion in US Sales

FDA cleared Amneal's generic lanreotide, and it launched immediately. Why more competition has not yet cut what patients pay for monthly injections.

Medical Daily · Sep 20

Jefferies hikes Navin Fluorine share price target, forecasts 14% upside. 4 reasons why

Jefferies has retained its Buy rating on Navin Fluorine International and raised its price target to Rs 9,405, citing growth prospects in CDMO, R32 and the Chemours project. The brokerage expects a 23% EPS CAGR through FY29, while the company’s Q1FY27 profit more than doubled year-on-year to Rs 243 crore.

The Economic Times · Sep 18

Montana's New Rules Let Licensed Clinics Sell Drugs That Cleared Only Phase 1 Safety Testing to Paying Patients

Montana now lets licensed clinics offer drugs that have passed only Phase 1 trials. Here is what that testing does and does not prove for patients.

Medical Daily · Sep 18

Your Medicare Drug Plan May Use a Different Pharmacy Network in 2027 — Check This Before December 7

You may have the same prescriptions, the same Medicare drug plan, and the same neighborhood pharmacy you’ve used for years and still face different prescription...

Saving Advice · Sep 17

Drugmakers and Research Partners Have Until October 30 to Apply for FDA Pilot Targeting First Human Trials

The FDA finalized its Expedited IND Pilot and is taking applications through Oct. 30. What changed, what an IND is, and why approvals are not faster.

Medical Daily · Sep 17

Loss-making vaccine maker agrees investors 'frustrated'

A listed Aussie healthcare group, under pressure after a whopping $3.7 billion loss, has acknowledged that it needs to win back the trust of shareholders.

AAP · Sep 17

Nebulized Tyvaso Enters FDA Review for Idiopathic Pulmonary Fibrosis, with a Decision Expected in Late April 2027

The FDA accepted United Therapeutics' application for nebulized Tyvaso in IPF, with a decision expected in late April 2027. What patients should know now.

Medical Daily · Sep 17